Cognition Therapeutics Secures FDA Pathway for Zervimesine in DLB Psychosis

Event summary

  • Cognition Therapeutics held a Type C meeting with the FDA on May 20, 2026 to discuss Phase 2 results and registrational study design for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.
  • The FDA provided positive feedback on the proposed path forward for advancing zervimesine into late-stage trials.
  • Zervimesine has demonstrated efficacy signals in the Phase 2 SHIMMER study (NCT05225415) and is generally well-tolerated.
  • The company plans to review formal FDA meeting minutes in June 2026.

The big picture

Cognition Therapeutics is positioning zervimesine as a potential first-in-class treatment for DLB psychosis, a market with limited therapeutic options. The positive FDA feedback marks a critical step in validating the company’s clinical strategy, though success will depend on executing a robust registrational program. The broader neurodegenerative disease space is increasingly focused on targeting toxic oligomers, a mechanism central to Cognition’s pipeline.

What we're watching

Regulatory Clarity
How the FDA’s formal minutes in June 2026 will shape the design and endpoints of the registrational study for zervimesine.
Clinical Execution
Whether Cognition can replicate the efficacy signals from the Phase 2 SHIMMER study in later-stage trials.
Competitive Positioning
The pace at which Cognition advances zervimesine compared to other DLB psychosis treatments in development.

Related topics

Drug Development